Eptinezumab Reduces Migraine Days in Hard-to-Treat Cases

Research Summary

In a new analysis from the DELIVER trial published in the European Journal of Neurology, researchers explored the effects of eptinezumab on monthly headache days (MHDs) in migraine sufferers who had previously failed 2-4 preventive treatments. Over a 24-week period followed by a 48-week extension, participants received eptinezumab or placebo. Findings revealed that 23% of those on eptinezumab reported fewer than 4 MHDs early on, increasing to 47% after a year. Notably, 9% experienced complete headache freedom. Those reducing MHDs to below 8 saw significant improvements in headache intensity and disease burden, highlighting eptinezumab's potential in difficult-to-treat cases.

Study Details

📄 Title: Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2-4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial.

👥 Research Team: Tassorelli C et al.

📚 Published In: Eur J Neurol

📅 Publication Date: 2025 Dec

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.